Table 1.
Patient, lesion, and treatment characteristics by whether the patient had recurrent disease (n=125).
| Variable | Coding | Overall (n=125) |
Locoregional recurrence | p-value | ||
|---|---|---|---|---|---|---|
| No (n=105) |
Yes (n=20) |
|||||
| n (%) | n (%) | n (%) | ||||
| Sex | Female | 13 (10.4) | 8 (7.6) | 5 (25) | 0.02 | |
| Male | 112 (89.6) | 97 (92.4) | 15 (75) | |||
| Differentiation | Poor | 27 (21.6) | 18 (17.1) | 9 (45) | 0.05 | |
| Moderate | 46 (36.8) | 39 (37.1) | 7 (35) | |||
| Well | 34 (27.2) | 32 (30.5) | 2 (10) | |||
| Not recorded | 18 (14.4) | 16 (15.2) | 2 (10) | |||
| Pre-treatment size (largest diameter) | <2.0 CM | 65 (52.0) | 60 (57.1) | 5 (25.0) | 0.02 | |
| ≥ 2.0 CM | 22 (17.6) | 15 (14.3) | 7 (35.0) | |||
| Not recorded | 38 (30.4) | 30 (28.6) | 8 (40.0) | |||
| Keratoacanthoma features | No | 50 (78.1) | 38 (36.2) | 12 (60.0) | 0.04 | |
| Yes | 14 (21.9) | 14 (13.3) | 0 (0) | |||
| Not recorded | 61 (48.8) | 53 (50.5) | 8 (40.0) | |||
| Perineural invasion (PNI) | No | 51 (40.8) | 43 (72.9) | 8 (44.4) | 0.03 | |
| Yes | 26 (20.8) | 16 (27.1) | 10 (55.6) | |||
| Not recorded | 48 (38.4) | 46 (43.8) | 2 (10.0) | |||
| PNI nerve caliber | <0.1 | 2 (7.7) | 1 (6.2) | 1 (10.0) | 0.76 | |
| >0.1 | 13 (50.0) | 8 (50.0) | 5 (50.0) | |||
| Not recorded | 11 (42.3) | 7 (43.8) | 4 (40.0) | |||
| LVI | No | 67 (53.6) | 56 (53.3) | 11 (55.0) | 0.016 | |
| Yes | 13 (10.4) | 7 (6.7) | 6 (30.0) | |||
| Not recorded | 45 (36.0) | 42 (40.0) | 3 (15.0) | |||
| Clark level | 1 | 2 (1.6) | 2 (1.9) | 0 (0) | 0.03 | |
| 2 | 17 (13.6) | 16 (15.2) | 1 (5.0) | |||
| 3 | 10 (8.0) | 10 (9.5) | 0 (0) | |||
| 4 | 4 (3.2) | 4 (3.8) | 0 (0) | |||
| 5 | 53 (61.6) | 36 (34.3) | 17 (85.0) | |||
| Not recorded | 39 (31.2) | 37 (35.2) | 2 (10.0) | |||
| Margins involved | No | 15 (93.8) | 11 (91.7) | 4 (100) | 0.55 | |
| Yes | 1 (6.3) | 1 (8.3) | 0 (0) | |||
| Total | 16 (100) | 12 (100) | 4 (100) | |||
| Immune status | Not involved | 104 (83.2) | 87 (82.9) | 17 (85) | 0.75 | |
| Not recorded | 5 (4) | 3 (2.9) | 2 (10) | |||
| Solid organ transplant | 11 (8.8) | 10 (9.5) | 1 (5) | |||
| Lymphoma | 1 (0.8) | 1 (1) | 0 (0) | |||
| HIV | 1 (0.8) | 1 (1) | 0 (0) | |||
| Chemotherapy | 1 (0.8) | 1 (1) | 0 (0) | |||
| Immunosuppressed | 2 (1.6) | 2 (1.9) | 0 (0) | |||
| Special features | No | 108 (86.4) | 94 (89.5) | 14 (70) | 0.006 | |
| Prior RT | 13 (10.4) | 7 (6.7) | 6 (30) | |||
| Over scars | 4 (3.2) | 4 (3.8) | 0 (0) | |||
| Recurrent disease | No | 99 (79.2) | 88 (83.8) | 11 (55) | 0.004 | |
| Yes | 26 (20.8) | 17 (16.2) | 9 (45) | |||
| Lymph node on imaging | No | 51 (40.8) | 39 (37.1) | 12 (60) | 0.004 | |
| Yes | 20 (16) | 14 (13.3) | 6 (30) | |||
| Not imaged | 54 (43.2) | 52 (49.5) | 2 (10) | |||
| Treatment | None | 1 (0.8) | 1 (1) | 0 (0) | <0.001 | |
| Mohs surgery | 57 (45.6) | 56 (53.3) | 1 (5) | |||
| WLE | 59 (47.2) | 44 (41.9) | 15 (75) | |||
| Topical treatment | 1 (0.8) | 1 (1) | 0 (0) | |||
| Radiation therapy | 1 (0.8) | 0 (0) | 1 (5) | |||
| Chemotherapy | 6 (4.8) | 3 (2.9) | 3 (15) | |||
| Adjuvant radiation | No | 116 (92.8) | 101 (96.2) | 15 (75) | 0.001 | |
| Yes | 9 (7.2) | 4 (3.8) | 5 (25) | |||
| LN excision with surgery | No | 94 (75.8) | 84 (80.0) | 10 (50) | 0.003 | |
| Yes | 30 (24.2) | 20 (19.0) | 10 (50) | |||
| Not recorded | 1 (0.80) | 1 (1.0) | 0 (0.0) | |||
| LN involved by tumor | No | 19 (15.2)) | 13 (12.4) | 6 (30) | 0.79 | |
| Yes | 11 (8.8) | 7 (6.7) | 4 (20) | |||
| Not recorded | 95 (76.0) | 85 (81.0) | 10 (50.0) | |||
| Extranodal extension | No | 27 (84.4) | 20 (87) | 7 (77.8) | 0.52 | |
| Yes | 5 (15.6) | 3 (13) | 2 (22.2) | |||
| Not recorded | 93 (74.4) | 82 (78.1) | 11 (55.0) | |||
| AJCC V.7 | 1 | 67 (53.6) | 62 (59.1) | 5 (25.0) | 0.001 | |
| 2 | 40 (32.0) | 31 (29.5) | 9 (45.0) | |||
| 3 | 6 (4.8) | 5 (4.8) | 1 (5.0) | |||
| 4 | 7 (5.6) | 3 (2.9) | 4 (20.0) | |||
| Not recorded | 5 (4.0) | 4 (3.8) | 1 (5.0) | |||
| Brigham’s woman hospital (BWH) staging | T1 | 33 (51.6) | 31 (60.8) | 2 (15.4) | 0.004 | |
| T2a | 9 (14.1) | 8 (15.7) | 1 (7.7) | |||
| T2b | 10 (15.6) | 5 (9.8) | 5 (38.5) | |||
| T3 | 12 (18.8) | 7 (13.7) | 5 (38.5) | |||
| Unable to stage | 61 (48.8) | 54 (51.4) | 7 (35.0) | |||
| Total | 125 (100) | 105 (100) | 20 (100) | |||
| AJCC V.8 | 1 | 77 (61.6) | 71 (67.6) | 6 (30.0) | 0.001 | |
| 2 | 13 (10.4) | 11 (10.5) | 2 (10.0) | |||
| 3 | 24 (19.2) | 17 (16.2) | 7 (35.0) | |||
| 4 | 7 (5.6) | 3 (2.9) | 4 (20.0) | |||
| Not recorded | 4 (3.2) | 3 (2.9) | 1 (5.0) | |||
| LN metastasis | No | 55 (44.0) | 48 (45.7) | 7 (35.0) | <0.001 | |
| Yes | 12 (9.6) | 4 (3.8) | 8 (40.0) | |||
| Not recorded | 58 (46.4) | 53 (50.5) | 5 (25.0) | |||
| Distant metastasis | No | 56 (44.8) | 47 (44.8) | 9 (45.0) | 0.005 | |
| Yes | 11 (8.8) | 5 (4.8) | 6 (30.0) | |||
| Not recorded | 58 (46.4) | 53 (50.5) | 5 (25.0) | |||
| Status | Alive | 79 (63.2) | 71 (67.6) | 8 (40.0) | 0.02 | |
| Dead | 46 (36.8) | 34 (32.4) | 12 (60.0) | |||
| Unknown | 0 (0) | 0 (0) | 0 (0) | |||
| Cause of death | SCC-related | 18 (39.1) | 8 (23.5) | 10 (83.3) | 0.001 | |
| Not SCC-related | 28 (60.9) | 26 (76.5) | 2 (16.7) | |||